$HIMS EXECUTIVE CALL SUMMARY: Hims & Hers Health Inc (05/11/26).
Hims & Hers delivered a strategically important but financially noisy Q1 2026 print that materially reframed the equity debate. The call was less a conventional beat-or-miss event and more a reset of the company’s operating model following the March 2026 pivot away from broad compounded GLP-1 commercialization and toward branded GLP-1 distribution, broader pharma partnerships, international scale, and higher-complexity clinical categories. The reported numbers were mixed to negative on near-term fundamentals: Q1 revenue of $608.1 million increased only 4% year-over-year, U.S. revenue declined 8% year-over-year to $529.9 million, gross margin compressed to 65% from 73%, adjusted EBITDA declined 51% year-over-year to $44.3 million, and GAAP net income swung to a $92.1 million loss from $49.5 million of net income. Subscriber growth remained positive, with subscribers up 9% year-over-year to 2.584 million, but monthly revenue per average subscriber declined to $80 from $85, indicating that subscriber growth did not translate into proportional monetization growth in the quarter. The company’s Q1 result was within prior company guidance but below Wall Street revenue expectations, and Reuters reported a surprise EPS loss versus consensus profit expectations, which explains the adverse after-hours market reaction despite the raised revenue outlook. (Hims Inc.)
The most important investment message from the call is that management is explicitly choosing accelerated scale over clean 2026 margin progression. Full-year 2026 revenue guidance was raised to $2.8 billion-$3.0 billion from prior guidance of $2.7 billion-$2.9 billion, but full-year adjusted EBITDA guidance was lowered to $275 million-$350 million from $300 million-$375 million. At the midpoint, revenue guidance increased $100 million, or 3.6%, while adjusted EBITDA guidance declined $25 million, or 7.4%, moving the midpoint adjusted EBITDA margin from approximately 12.1% to 10.8%. This is a clear mix and reinvestment reset: the company is adding revenue, but the incremental revenue is currently lower margin and requires incremental technology, operations, clinical, international, and partnership investment. (Hims Inc.)
Q1 actual performance versus prior guidance was acceptable but not impressive. The company had previously guided Q1 2026 revenue to $600 million-$625 million and adjusted EBITDA to $35 million-$55 million. Actual revenue of $608.1 million was inside the range but below the $612.5 million midpoint, and actual adjusted EBITDA of $44.3 million was inside the range but slightly below the $45 million midpoint. The problem was not failure to hit management’s own Q1 range; the problem was that the call revealed a lower-quality growth transition than the market had likely underwritten. The prior full-year 2026 outlook also assumed continued access to compounded semaglutide through the platform and no change to current business relationships, while the updated outlook reflects the strategic pivot toward branded GLP-1s and explicitly excludes potential Eucalyptus contribution. This distinction is critical because the guide has changed not only numerically but structurally. (Hims Inc.)
The most consequential operational disclosure was management’s claim that the branded GLP-1 pivot is already producing record-scale demand. Andrew Dudum stated, “Within six weeks of introducing direct access to Novo Nordisk’s GLP-1 products to our platform, we have fulfilled more than 125,000 shipments for Wegovy products.” Yemi Okupe added that the company is “on track to add north of 100,000 new subscribers per month within our weight loss specialty,” with nearly 90% of these users downloading the app and the average subscriber interacting with a provider 3 times in the 1st month. These statements indicate that the branded GLP-1 transition is not demand-constrained at current price points; instead, the debate shifts to gross margin, retention, contribution dollars, manufacturer dependence, customer acquisition efficiency, and whether this GLP-1-driven intake funnel can be converted into durable multi-specialty relationships.
The weight-loss pivot is strategically rational but economically unproven at the new scale. On 03/09/26, Hims announced a collaboration with Novo Nordisk and said it would no longer advertise compounded GLP-1 offerings, while offering FDA-approved GLP-1 medications and maintaining limited access to compounded GLP-1s only where clinically necessary. The agreement brought Ozempic and Wegovy pills and injections onto the platform and led Novo Nordisk to dismiss its lawsuit without prejudice. Reuters reported that Novo would sell approved Wegovy and Ozempic through Hims at Novo self-pay prices and that Hims would stop advertising compounded GLP-1s, while still offering compounded versions when clinically necessary. This is strategically material because it reduces one of the central existential overhangs around the GLP-1 business: the risk that Hims’ weight-loss growth was dependent on legally fragile, regulatorily controversial compounded alternatives. (Hims Inc.)
The pivot also introduces a new strategic dependency. Branded GLP-1 access makes Hims more aligned with FDA-approved pharmaceutical channels, but it also shifts bargaining power toward Novo Nordisk, Eli Lilly, and future branded manufacturers. In the old model, Hims captured more economics through personalized compounded products and vertically integrated pharmacy capabilities. In the new model, Hims must prove that its distribution, clinical engagement, app experience, adherence support, cross-sell, and data feedback loops generate sufficient value for manufacturers and patients to sustain attractive economics. Yemi Okupe’s Q&A answer that branded and compounded customers are “roughly comparable” on a contribution-dollar basis was one of the most important comments on the call, but it requires empirical validation over several cohorts. A comparable contribution-dollar profile can coexist with a lower gross margin percentage if revenue recognition is gross and branded drug costs are higher. The equity market will likely require proof through cohort retention, repeat orders, CAC trends, and realized adjusted EBITDA rather than accepting the statement at face value.
The gross margin reset is the clearest near-term evidence that the new revenue mix is less attractive on reported margins. Q1 GAAP gross margin declined to 65% from 73% in Q1 2025, with $28.5 million of restructuring and related charges in cost of revenue. Adjusted gross margin was 70%, still down 3 pts year-over-year even after excluding the restructuring charge. Management guided to continued gross margin compression as weight loss, labs, and international become larger parts of the mix, and Yemi Okupe later indicated that “a couple of points of degradation” could occur over the coming quarters. This is not only an accounting issue; it is a mix issue. The company is moving from higher-margin tenured specialties toward lower-margin but potentially larger and more strategic categories. (Hims Inc.)
Operating expense trends were also mixed. Marketing expense declined to $222.0 million from $231.2 million and improved to approximately 36.5% of revenue from 39.5% in Q1 2025, validating management’s claim of improving marketing efficiency. However, this improvement was more than offset by higher operating complexity elsewhere: operations and support expense increased 53% year-over-year, technology and development increased 57%, and G&A increased 126%, with G&A affected by legal settlement costs, M&A costs, and stock-based compensation. Adjusted operating expenses still increased meaningfully, indicating that the reinvestment cycle is not limited to unusual charges. The core margin question is whether technology, AI, pharmacy verticalization, and larger cohorts can bend the cost curve in 2027 and beyond, as management suggested, or whether the company has structurally entered a lower-margin phase due to branded drug mix, international expansion, and more clinically complex specialties. (Hims Inc.)
Cash generation was a stabilizing factor but should not be over-interpreted. Q1 operating cash flow was $89.4 million and free cash flow was $53.0 million, up modestly from $50.1 million in Q1 2025, despite the GAAP loss. This demonstrates that the company retains meaningful cash-generative characteristics and is not being forced to fund the transition with external capital in the near term. However, cash flow quality requires monitoring because the cash flow statement included a $116.2 million receivables use of cash and a $167.6 million accounts payable source of cash. The balance sheet remains strong, with $222.3 million of cash and $528.6 million of short-term available-for-sale investments at quarter-end, or approximately $750.9 million combined, but the Eucalyptus closing payment and deferred obligations will reduce flexibility. (Hims Inc.)
The updated guide embeds a significant 2H26 profitability inflection. Q2 guidance calls for $680 million-$700 million of revenue and $35 million-$55 million of adjusted EBITDA, implying approximately 25%-28% year-over-year revenue growth and only a 5%-8% adjusted EBITDA margin. At the midpoint, Q2 revenue increases 13.5% sequentially from Q1, while adjusted EBITDA is essentially flat. Using the full-year midpoint of $2.9 billion of revenue and $312.5 million of adjusted EBITDA, the implied 2H26 revenue after Q1 and Q2 midpoint guidance is approximately $1.602 billion, or about $801 million per quarter, with implied 2H26 adjusted EBITDA of approximately $223 million, or about $111.6 million per quarter. That equates to an implied 2H26 adjusted EBITDA margin of approximately 13.9%, versus 7.3% in Q1 and 6.5% at the Q2 midpoint. Therefore, the 2026 guide is not conservative on back-half operating leverage; it requires cohort stacking, G&A leverage, marketing efficiency, and lower friction in the branded transition to materialize quickly. (Hims Inc.)
The strategic argument for the branded pivot is stronger than the near-term P&L optics. Hims’ historical GLP-1 opportunity was vulnerable to FDA action, pharma litigation, and the normalization of drug supply. The FDA had already stated on 02/06/26 that it intended to take “decisive steps” to restrict GLP-1 APIs used in non-FDA-approved compounded drugs that were being mass-marketed, including by Hims & Hers and other compounding pharmacies, and the FDA warned that failure to address violations could result in seizure or injunction. On 03/03/26, the FDA also announced 30 warning letters to telehealth companies for false or misleading claims around compounded GLP-1 products, reiterating that compounded drugs are not FDA-approved and are not the same as generics. Against that backdrop, the Novo collaboration transforms a regulatory liability into a distribution partnership, but at the cost of margin uncertainty and manufacturer dependency. (U.S. Food and Drug Administration)
The investment debate is therefore shifting from “Is compounded GLP-1 growth sustainable?” to “Can Hims become the preferred digital distribution and longitudinal care layer for branded pharma, diagnostics, labs, and emerging wellness categories?” Andrew Dudum explicitly framed the company as a platform for “pharma, biotech, and diagnostic companies” to reach consumers, and later stated that there are “probably 2 dozen” conversations taking place domestically and globally across pharma, biotech, devices, and diagnostics. This is a meaningful broadening of the business model. If manufacturers view Hims as a high-conversion, high-retention, medically compliant demand-generation channel, then Hims can become a scaled distribution partner rather than a regulatory arbitrage vehicle. If manufacturers ultimately internalize the consumer funnel or pressure economics, Hims’ role could compress into a lower-margin customer acquisition and care-support layer.
International expansion was a major positive in the quarter and materially offset domestic softness. Rest-of-world revenue increased nearly 10x year-over-year to $78.2 million and represented approximately 12.9% of Q1 revenue, up from approximately 1.2% in Q1 2025. Sequentially, rest-of-world revenue increased 22.8%, while U.S. revenue declined 4.4%. This mix shift supports management’s argument that Hims is becoming a global consumer health platform, but it also makes consolidated margins less comparable to the older U.S.-centric, higher-margin model. The ZAVA and Livewell acquisitions appear to be contributing meaningfully, and Eucalyptus is intended to accelerate the same playbook across Australia, the UK, Germany, Japan, and Canada. (Hims Inc.)
The pending Eucalyptus acquisition increases both strategic upside and execution risk. Eucalyptus has served more than 775,000 customers, has ARR north of $450 million, and operates across Australia, the UK, Germany, Japan, and Canada. The transaction is valued at up to $1.15 billion, with approximately $240 million payable in cash at closing and the remaining consideration consisting of guaranteed deferred payments over 18 months and earnouts through early 2029, with Hims retaining the option to settle the majority of deferred and earnout payments in cash or stock. Strategically, this can accelerate global category leadership and deepen pharma partnership relevance; financially, it increases acquisition integration risk, potential dilution risk, cash-allocation complexity, and exposure to multi-jurisdiction healthcare compliance regimes. (Hims Inc.)
The call’s AI discussion was unusually central and was designed to reposition Hims as a technology and data company rather than a telehealth marketplace. Mo Elshenawy described a lean AI organization with nearly 40 members, modularized platform architecture, a no-code commercial engine, configurable clinical workflows, AI Copilot tools for care coaches, Labs AI for biomarker interpretation, and an upcoming weight-loss companion. The key strategic quote was: “This means we are generating clinician-verified training signals for our models. This is the highest-quality label in AI any company can hope for, and it can’t be acquired.” The claim is directionally important because Hims can plausibly collect intake, diagnosis, treatment, provider decision, adherence, and outcome data in 1 integrated stack. However, the call did not quantify AI-driven cost savings, retention lift, provider productivity gains, or clinical outcomes improvement. Therefore, AI remains a potentially powerful margin and moat narrative, but the 2026 guide does not yet show clear financial evidence of AI leverage.
The AI strategy could be highly relevant to valuation if it converts into measurable retention and cost-to-serve advantages. Traditional telehealth platforms often struggle with episodic usage, limited longitudinal data, and low switching costs. Hims is attempting to build a multi-condition, longitudinal, data-rich relationship in which labs, wearables, biomarker interpretation, provider messaging, medication titration, and cross-specialty recommendations reinforce each other. Andrew Dudum described the long-term vision as multiple agents supporting each stage of the customer journey across every specialty. Strategically, this is the correct direction for a consumer health platform seeking durable lifetime value, but it also increases regulatory, privacy, model-governance, and medical-liability complexity. The company emphasized that independent providers retain clinical decision-making responsibility, an important boundary given healthcare AI scrutiny.
The new specialty strategy is a credible attempt to expand the platform beyond hair loss, sexual health, and weight loss, but it carries lower-margin and higher-complexity characteristics. Testosterone, menopause, labs, and at-home blood collection are intended to move Hims from episodic treatment to proactive care. Management disclosed that testosterone is already serving tens of thousands of men and that 95% of Hims customers relying on the platform for testosterone support saw increased testosterone levels within 2 months. The YourBio acquisition is strategically relevant because painless at-home blood collection could reduce friction around labs and biomarker-based care, strengthening retention and enabling more clinically sophisticated offerings. The tradeoff is that these categories require more medical oversight, more operational talent, more compliance infrastructure, and likely more variable cost than legacy subscription products.
Peptides emerged as a significant new call topic and should be treated as upside optionality rather than a base-case revenue driver. Andrew Dudum stated that the company’s medical team sees “meaningful potential in several peptide therapies” and that Hims would not launch peptides until it meets “very high standards.” In Q&A, he stated the company may not be “first,” but intends to be “best,” emphasizing validated supply chains, clinical protocols, and data transparency. This matters because Hims has more than 1 million square feet of 503A compounding infrastructure and has acquired a U.S.-based peptide facility, positioning the company to pursue personalized dosing and domestic API control if the regulatory path opens. However, the FDA’s upcoming Pharmacy Compounding Advisory Committee meeting on 07/23/26-07/24/26 will evaluate only specific bulk drug substances for possible inclusion on the 503A Bulks List, including BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax, and Epitalon. Inclusion on a compounding list would not be equivalent to FDA approval of these peptides as drugs. (U.S. Food and Drug Administration)
The peptide opportunity also increases headline and regulatory risk. Reuters reported that the FDA previously barred compounding pharmacies from manufacturing 14 peptides in 2023 due to concerns including immunogenicity, toxicity, impurity, and insufficient human testing, and that most of these peptides have not been adequately tested in humans. Hims is attempting to present itself as the compliant, physician-supervised alternative to the gray market, which is strategically sensible. However, after the GLP-1 compounding controversy, any move into peptides will be scrutinized by regulators, manufacturers, clinicians, and investors. The opportunity could become a differentiated growth vector if Hims sets the compliance standard, but it could also renew concerns that the company is pushing into regulatory frontiers to replace GLP-1 compounding economics. (Reuters)
The call reinforced the 2030 targets of at least $6.5 billion in revenue and $1.3 billion in adjusted EBITDA. Those targets remain achievable only if the company can sustain high revenue growth while materially expanding margins after 2026. From the midpoint of the updated 2026 guide, the 2030 revenue target implies approximately 22% annual revenue growth through 2030, while the adjusted EBITDA target implies approximately 43% annual adjusted EBITDA growth from the 2026 midpoint. The revenue CAGR requirement is plausible for a scaled consumer health platform with GLP-1, international, new specialties, labs, and M&A contribution. The EBITDA CAGR requirement is much more demanding and requires a decisive post-2026 margin inflection. This makes 2027 cost-to-serve reduction, AI productivity, pharmacy efficiencies, and gross margin stabilization central to the long-term equity story.
The quarter’s core positive was that Hims appears to have preserved, and potentially expanded, its weight-loss demand funnel despite the pivot away from broad compounding. The GLP-1 issue was the dominant investor concern entering the quarter, and management’s disclosures suggest that branded GLP-1 products are bringing large volumes of customers onto the platform. The company’s claim that it can add >100,000 new weight-loss subscribers per month is a powerful top-line signal, especially if these customers exhibit high app engagement and recurring provider interaction. The presence of branded products may also expand the addressable market by reducing patient concerns about unapproved compounded medications and by aligning the company with major manufacturers.
The core negative was that the economics of this larger opportunity are less certain and less profitable in 2026. The company raised revenue but cut adjusted EBITDA, guided Q2 to a 5%-8% adjusted EBITDA margin, and signaled gross margin compression. At the midpoint, 2026 adjusted EBITDA of $312.5 million would be slightly below 2025 adjusted EBITDA of $318.0 million despite midpoint revenue growth of approximately 23.5%. That is the most important financial fact from the call. It indicates that 2026 is not an operating leverage year; it is an investment, transition, and mix-rebuild year. (Hims Inc.)
The market reaction was understandable. Reuters reported that shares fell >12% in extended trading to $25.55 after the company missed Q1 revenue estimates and posted a surprise loss, even though Q2 revenue guidance was ahead of analyst estimates and full-year revenue guidance was raised. The adverse reaction reflects investor concern about earnings quality, not merely reported revenue. It also reflects skepticism that back-half EBITDA acceleration can offset lower gross margin, strategic pivots, acquisition complexity, and regulatory uncertainty. (Reuters)
The most objective interpretation is that the call reduced near-term earnings visibility while increasing strategic clarity. Hims is moving away from the highest-risk version of its GLP-1 strategy and toward a platform model that can plausibly partner with drugmakers, diagnostics companies, and device companies. That is a higher-quality long-term narrative if the economics work. However, the near-term model now depends on lower-margin branded product revenue, heavier technology and operational spend, international expansion, and 2H26 operating leverage that has not yet been proven. The company is asking investors to underwrite a transition period based on demand signals rather than current margin evidence.
Investment implications are therefore 2-sided. The positive case is that Hims is becoming a scaled consumer healthcare distribution platform with strong brand awareness, large patient volumes, improving marketing efficiency, positive free cash flow, broadening international exposure, and a growing set of manufacturer relationships. Under that case, branded GLP-1s become a customer acquisition wedge, AI and labs improve retention, international markets expand TAM, and operating leverage returns in 2027 as the new model scales. The negative case is that Hims’ prior GLP-1 profitability was structurally dependent on compounded product economics that cannot be replicated in branded channels, while new categories and international expansion require ongoing investment and expose the company to higher compliance costs. Under that case, revenue growth remains strong but EBITDA intensity stays elevated, and the 2030 margin target becomes increasingly difficult.
The decisive next proof points are not simply revenue growth. The most important indicators are branded GLP-1 retention beyond the 1st month, refill rates under 1-month cadence, cross-sell into non-weight-loss categories, marketing expense as a % of revenue, adjusted gross margin after the restructuring period, realized contribution dollars per branded weight-loss customer, the magnitude of gross margin compression in Q2 and Q3, and whether the implied 2H26 adjusted EBITDA ramp begins to materialize. Evidence that >100,000 monthly weight-loss subscriber additions produce high retention and multi-category engagement would materially strengthen the bull case. Evidence that branded GLP-1 cohorts churn quickly, require persistent high CAC, or dilute gross margin more than expected would materially weaken it.
In sum, Q1 2026 should be viewed as a high-stakes transition quarter. The call was strategically constructive because it showed early demand traction after the Novo pivot and a broader platform ambition across AI, labs, testosterone, menopause, peptides, branded pharma, and international markets. The call was financially dilutive because it lowered EBITDA expectations, highlighted margin compression, produced a GAAP loss, and required a significant 2H26 profitability step-up. The equity story is now less about whether Hims can grow and more about whether it can convert a much larger, lower-margin, more regulated, and more global healthcare funnel into durable high-margin EBITDA by 2027-2030.
COMPANY EMPLOYEES ON THE CALL
Andrew Dudum, Co-Founder and Chief Executive Officer
Bill Newby, Head of Investor Relations
Mo Elshenawy, Chief Technology Officer
Yemi Okupe, Chief Financial Officer
